Clorazepate dipotassium | CAS# 57109-90-7 | Antianxiety agent

MedKoo Cat#: 571306 | Name: Clorazepate dipotassium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clorazepate dipotassium is a water-soluble benzodiazepine derivative effective in the treatment of anxiety. It has also muscle relaxant and anticonvulsant actions and thus has been shown to suppress seizures.

Chemical Structure

Clorazepate dipotassium

CAS#57109-90-7 (dipotassium)

Theoretical Analysis

MedKoo Cat#: 571306

Name: Clorazepate dipotassium

CAS#: 57109-90-7 (dipotassium)

Chemical Formula: C16H11ClK2N2O4

Exact Mass: 0.0000

Molecular Weight: 408.92

Elemental Analysis: C, 47.00; H, 2.71; Cl, 8.67; K, 19.12; N, 6.85; O, 15.65

Price and Availability

This product was removed for the commercial reasons.

Related CAS #

23887-31-2 (free acid) 5991-71-9 (monopotassium) 57109-90-7 (dipotassium)

Synonym

Clorazepate dipotassium; Chlorazepam; Mendon; Transilium; AB 35616; AB-35616; AB35616

IUPAC/Chemical Name

1H-1,4-Benzodiazepine-3-carboxylic acid, 7-chloro-2,3-dihydro-2-oxo-5-phenyl-, potassium salt compd. with potassium hydroxide (1:1)

InChi Key

QCHSEDTUUKDTIG-UHFFFAOYSA-L

InChi Code

InChI=1S/C16H11ClN2O3.2K.H2O/c17-10-6-7-12-11(8-10)13(9-4-2-1-3-5-9)19-14(16(21)22)15(20)18-12;;;/h1-8,14H,(H,18,20)(H,21,22);;;1H2/q;2*+1;/p-2

SMILES Code

O=C(C1C(NC2=CC=C(Cl)C=C2C(C3=CC=CC=C3)=N1)=O)[O-].[K+].[K+].[OH-]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 408.92 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Pineda S, Anzola B, Olivares A, Ibáñez M. Fluoxetine combined with clorazepate dipotassium and behaviour modification for treatment of anxiety-related disorders in dogs. Vet J. 2014 Mar;199(3):387-91. doi: 10.1016/j.tvjl.2013.11.021. Epub 2013 Dec 1. PubMed PMID: 24439470. 2: Mielke L, Breinbauer B, Schubert M, Kling M, Entholzner E, Hargasser S, Hipp R. [Comparison of the effectiveness of orally administered clorazepate dipotassium and nordiazepam on preoperative anxiety]. Anaesthesiol Reanim. 1995;20(6):144-8. German. PubMed PMID: 8652038. 3: Amano K, Takamatsu J, Ogata A, Katsuragi S, Miyazaki C, Deshimaru M, Sumiyoshi S, Miyakawa T. Effect of dipotassium clorazepate on amygdaloid-kindling and comparison between amygdaloid- and hippocampal-kindled seizures in rats. Eur J Pharmacol. 1999 Dec 3;385(2-3):111-7. PubMed PMID: 10607866. 4: Kretz FJ, Gonzales I, Peidersky P. [Oral premedication with clorazepate dipotassium. Comparison with oral premedication with flunitrazepam and intramuscular premedication with promethazine, pethidine and atropine in adults]. Anaesthesist. 1993 Jan;42(1):15-22. German. PubMed PMID: 8447567. 5: Berendes E, Scherer R, Rotthove K, Prien T. [Anxiolysis, sedation, and stress reduction following oral premedication with midazolam in adults. A comparison with dipotassium clorazepate and placebo]. Anaesthesist. 1996 Jun;45(6):506-11. German. PubMed PMID: 8767563. 6: Amano K, Takamatu J, Kaneyama H, Miyazaki C, Deshimaru M, Sumiyoshi S, Ogata A, Miyakawa T. Anticonvulsant effects of dipotassium clorazepate on hippocampal kindled seizures in rats. Psychiatry Clin Neurosci. 1998 Aug;52(4):459-62. PubMed PMID: 9766699. 7: Perez GG, Tudor R. A post-marketing surveillance survey on the use of dipotassium clorazepate in clinical practice in the Philippines. Curr Med Res Opin. 1993;13(3):175-81. PubMed PMID: 8222745. 8: Anrys P, Magnette A, Jamart J, Galanti L, Hecq JD. [Physical compatibility of a mixture of alizapride and clorazepate in flexible infusion bags of 100 ml of 5% glucose]. J Pharm Belg. 2014 Sep;(3):38-9. French. PubMed PMID: 25226762. 9: Staak M, Moosmayer A. [Pharmacokinetic studies on interactions between dipotassium clorazepate and alcohol after oral application (author's transl)]. Arzneimittelforschung. 1978;28(7):1187-91. German. PubMed PMID: 39573. 10: Moodley P, Golombok S, Lader M. Effects of clorazepate dipotassium and placebo on psychomotor skills. Percept Mot Skills. 1985 Dec;61(3 Pt 2):1121-2. PubMed PMID: 2869470. 11: Hanna S, Diana F, Slevinski J, Veronich K, Lachman L. Differential pulse polarographic determination of clorazepate monopotassium and dipotassium. J Pharm Sci. 1978 Dec;67(12):1723-5. PubMed PMID: 31451. 12: Uhlig T, Schön J, Schmucker P. [Optimizing anesthesiologic premedication with reference to biopsychological theories. Exemplified by the effect of dipotassium clorazepate and zolpidem in combination with promethazine]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1997 Oct;32(3 Suppl):S355-64. German. PubMed PMID: 9445577. 13: Llano López LH, Caif F, Fraile M, Tinnirello B, de Gargiulo AI, Lafuente JV, Baiardi GC, Gargiulo PA. Differential behavioral profile induced by the injection of dipotassium chlorazepate within brain areas that project to the nucleus accumbens septi. Pharmacol Rep. 2013;65(3):566-78. PubMed PMID: 23950579. 14: Ma LL, Freret T, Lange M, Bourgine J, Coquerel A, Lelong-Boulouard V. Benzodiazepines increase the reward effects of buprenorphine in a conditioned place preference test in the mouse. Fundam Clin Pharmacol. 2014 Dec;28(6):681-9. doi: 10.1111/fcp.12072. Epub 2014 Apr 17. PubMed PMID: 24617653. 15: Laube T, Krohner H, Franke GH, Brockmann C, Steuhl KP. Clorazepate dipotassium versus midazolam for premedication in clear corneal cataract surgery. J Cataract Refract Surg. 2003 Oct;29(10):1956-61. PubMed PMID: 14604717. 16: El-Bardicy MG, Bebawy LI, Amer MM. Stability-indicating method for the determination of clorazepate dipotassium-II. Via N-desmethyldiazepam and determination of its degradation products. Talanta. 1992 Oct;39(10):1323-7. PubMed PMID: 18965536. 17: Carrigan PJ, Chao GC, Barker WM, Hoffman DJ, Chun AH. Steady-state bioavailability of two clorazepate dipotassium dosage forms. J Clin Pharmacol. 1977 Jan;17(1):18-28. PubMed PMID: 13089. 18: Elrod L Jr, Shada DM, Taylor VE. High-performance liquid chromatographic analysis of clorazepate dipotassium and monopotassium in solid dosage forms. J Pharm Sci. 1981 Jul;70(7):793-5. PubMed PMID: 6115049. 19: Wallis TD, Vallé-Jones JC, Craven JR, Hanks GW, Stonier PD. Single daily dose treatment of anxiety with clobazam or dipotassium clorazepate. Br J Clin Pharmacol. 1979;7 Suppl 1:123S-127S. PubMed PMID: 35192; PubMed Central PMCID: PMC1429503. 20: Irimajiri M, Crowell-Davis SL. Animal behavior case of the month. Separation anxiety. J Am Vet Med Assoc. 2014 Nov 1;245(9):1007-9. doi: 10.2460/javma.245.9.1007. PubMed PMID: 25313810.

View History

Clorazepate monopotassium

MedKoo CAT#: 534571

CAS#: 5991-71-9